Bitistatin
Latest Information Update: 19 Feb 2008
At a glance
- Originator Merck & Co
- Class Antiplatelets
- Mechanism of Action Fibrinogen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Thrombosis
Most Recent Events
- 04 Nov 1997 No-Development-Reported for Ischaemic heart disorders in USA (unspecified route)
- 04 Nov 1997 No-Development-Reported for Thrombosis in USA (unspecified route)
- 24 Oct 1994 Preclinical development for Ischaemic heart disorders in USA (unspecified route)